Somewhat Positive News Coverage Somewhat Unlikely to Affect Regeneron Pharmaceuticals (REGN) Share Price
News headlines about Regeneron Pharmaceuticals (NASDAQ:REGN) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.6029164386422 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- Quant Score Limits Regeneron Pharmaceuticals (REGN) Rating (investorplace.com)
- Regeneron to Report Third Quarter 2017 … (ih.advfn.com)
- $REGN – Traders Buy Regeneron Pharmaceuticals, Inc. #REGN on Weakness (4-traders.com)
- Internationally Acclaimed Writer and Executive Producer of HBO’s The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis (finance.yahoo.com)
- Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017 (finance.yahoo.com)
Several research analysts have recently issued reports on REGN shares. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Robert W. Baird cut shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price on the stock. in a report on Tuesday, August 1st. Jefferies Group LLC restated a “hold” rating and issued a $500.00 target price (up previously from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Credit Suisse Group cut shares of Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 target price on the stock. in a report on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $489.92.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 445.68 on Tuesday. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $543.55. The stock has a market cap of $47.26 billion, a price-to-earnings ratio of 44.71 and a beta of 1.63. The firm has a 50-day moving average price of $456.72 and a 200-day moving average price of $455.81.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same period last year, the business posted $2.82 earnings per share. The firm’s revenue was up 21.2% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals will post $14.94 earnings per share for the current fiscal year.
In other news, Director Charles A. Baker sold 2,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares in the company, valued at $4,950,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 89,468 shares of company stock valued at $42,312,448. Company insiders own 10.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Regeneron Pharmaceuticals (REGN) Share Price” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/17/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-regeneron-pharmaceuticals-regn-share-price.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.